2010
DOI: 10.1111/j.1349-7006.2010.01579.x
|View full text |Cite
|
Sign up to set email alerts
|

Pitavastatin inhibits azoxymethane‐induced colonic preneoplastic lesions in C57BL/KsJ‐db/db obese mice

Abstract: Obesity and related metabolic abnormalities are risk factors for colorectal cancer. A state of chronic inflammation and adipocytokine imbalance may play a role in colorectal carcinogenesis. Statins, which are commonly used for the treatment of hyperlipidemia, are known to possess anti-inflammatory effects. Statins also exert chemopreventive properties against various cancers. The present study examined the effects of pitavastatin, a recently developed lipophilic statin, on the development of azoxymethane (AOM)… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

9
68
1

Year Published

2011
2011
2016
2016

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 57 publications
(78 citation statements)
references
References 50 publications
(100 reference statements)
9
68
1
Order By: Relevance
“…Dietary energy restriction suppresses mammary tumorigenesis in rats by increasing the levels of activated AMPK (45). Pitavastatin, a lipophilic statin, was found to prevent obesity-and diabetes-related colon carcinogenesis in mice by activating AMPK in the colonic mucosa (29). These reports suggest the possibility that activation of AMPK by ACR aided in suppressing the development of obesity-related liver cells adenomas, as observed in the present study.…”
Section: Discussionsupporting
confidence: 70%
See 2 more Smart Citations
“…Dietary energy restriction suppresses mammary tumorigenesis in rats by increasing the levels of activated AMPK (45). Pitavastatin, a lipophilic statin, was found to prevent obesity-and diabetes-related colon carcinogenesis in mice by activating AMPK in the colonic mucosa (29). These reports suggest the possibility that activation of AMPK by ACR aided in suppressing the development of obesity-related liver cells adenomas, as observed in the present study.…”
Section: Discussionsupporting
confidence: 70%
“…Previously described primary antibodies for RXRa , ERK, phosphorylated ERK (p-ERK), Stat3, p-Stat3, AMP-activated kinase (AMPK), p-AMPK, and GAPDH were used (15,22,28,29). The DN-197 antibody is considered a specific antibody for the p-RXRa protein (22,23).…”
Section: Protein Extraction and Western Blot Analysismentioning
confidence: 99%
See 1 more Smart Citation
“…Previously described primary antibodies for IGF-1R, phosphorylated IGF-1R (p-IGF-1R), ERK, p-ERK, Akt, p-Akt, Stat3, p-Stat3, AMP-activated kinase (AMPK), p-AMPK, glycogen synthase kinase (GSK)-3b, p-GSK-3b, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used (16,26,27). The primary antibody for c-Jun NH 2 -terminal kinase (JNK) and p-JNK was obtained from Cell Signaling Technology.…”
Section: Protein Extraction and Western Blot Analysismentioning
confidence: 99%
“…The cDNA was amplified from 0.2 mg of total RNA, using the SuperScript III First-Strand Synthesis System (Invitrogen). Quantitative real-time reverse transcriptase PCR (RT-PCR) analysis was done using specific primers that amplify the TNF-a, IL-6, IL-1b, IL-18, and b-actin genes, as described previously (26,28).…”
Section: Protein Extraction and Western Blot Analysismentioning
confidence: 99%